Latest Mesoblast News & Updates

See the latest news and media coverage for Mesoblast. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Mesoblast

Biotechnology company developing allogeneic cell therapies

mesoblast.com
Headquarters
Melbourne, Australia
Founded year
2004
Company type
Public company
Number of employees
100–200
Industry
Pharmaceuticals

Last updated

Latest news about Mesoblast

In short: Mesoblast achieved significant commercial growth with its therapy Ryoncil, reporting $115 million in FY2026 revenue and pipeline expansion.

Company announcements

Mesoblast

Mesoblast reports Ryoncil net revenues

US$36M for the quarter and US$115M for the year; adult SR-aGvHD registration trial is enrolling, IND cleared for DMD, and 300 patients treated in the CLBP Phase 3 trial.

Mesoblast

Mesoblast released a notification about unquoted securities

The filing provides details on MSB unquoted securities and includes a PDF attachment.

Unlock all announcements with a

Media coverage

24/7 Wall St.

Mesoblast (MESO) Q2 2026 Earnings

Mesoblast posted $115 million in first-year Ryoncil revenue, crushing the $52 million estimate, but the full-year tally obscures a stunning second-half acceleration that sent $66.5...

The Globe and Mail

Mesoblast Advances Rexlemestrocel‑L BLA for High‑Risk LVAD Heart Failure Patients

An update from Mesoblast Limited ( (AU:MSB)) is now available. Mesoblast has received a U.S. FDA Biologics License Application filing number and requested modular review...

Unlock all articles with a

Never miss news about Mesoblast

Track Mesoblast and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.